Patents by Inventor Takushi Kaneko

Takushi Kaneko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030013665
    Abstract: This invention relates to compounds of the formula 1
    Type: Application
    Filed: July 24, 2002
    Publication date: January 16, 2003
    Inventor: Takushi Kaneko
  • Patent number: 6492342
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein a, b, X, Y, Z, R1, R2, and R3 are as defined herein. The compounds of formula I are antibacterial and antiprotozoal agents useful for treating various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I, to methods of treating bacterial and protozoal infections by administering the compounds of formula I, and to methods for preparing compounds of formula I.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: December 10, 2002
    Assignee: Pfizer Inc.
    Inventor: Takushi Kaneko
  • Publication number: 20020156027
    Abstract: This invention relates to compounds of the formula 1 1
    Type: Application
    Filed: April 5, 2002
    Publication date: October 24, 2002
    Inventors: William T. McMillen, Takushi Kaneko
  • Publication number: 20020156026
    Abstract: This invention relates to compounds of formula (1) and to pharmaceutically acceptable salts thereof. The compounds of formula (1) are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula (1) and to methods of treating bacterial infections by administering the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1) and to intermediates useful in such preparation.
    Type: Application
    Filed: February 26, 2002
    Publication date: October 24, 2002
    Inventors: Brain Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
  • Patent number: 6420343
    Abstract: This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof wherein X1, X2, R2 and R6 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: July 16, 2002
    Assignee: Pfizer Inc
    Inventors: Wei-Guo Su, Takushi Kaneko, Yong-Jin Wu
  • Patent number: 6420536
    Abstract: The invention relates to a method of preparing compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial protozoa infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: July 16, 2002
    Assignee: Pfizer Inc
    Inventors: Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
  • Patent number: 6407074
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 18, 2002
    Assignee: Pfizer Inc
    Inventors: Brian Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
  • Patent number: 6403776
    Abstract: The invention relates to a method of preparing a macrolide antibiotic of the formula wherein R1, R2, R3, R4, R5 are defined above. These antibiotics are useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. The invention also includes novel compounds made by the preparation of the macrolide antibiotic.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David H. B. Ripin, Brian C. Vanderplas, Takushi Kaneko, William T. McMillen, Robert W. McLaughlin
  • Publication number: 20020065235
    Abstract: This invention relates to compounds of the formula 1 1
    Type: Application
    Filed: February 26, 2001
    Publication date: May 30, 2002
    Inventors: Takushi Kaneko, William Thomas McMillen, Wei-Guo Su, Hongjuan Zhao
  • Publication number: 20020061858
    Abstract: The invention relates to compounds of the formula 1
    Type: Application
    Filed: November 21, 2001
    Publication date: May 23, 2002
    Inventors: Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
  • Publication number: 20020052328
    Abstract: This invention relates to compounds of the formula 1
    Type: Application
    Filed: June 26, 2001
    Publication date: May 2, 2002
    Inventors: Takushi Kaneko, William Thomas McMillen
  • Patent number: 6372781
    Abstract: Spirolaxine, the compound of formula (I) wherein R is H, and the novel compounds of formula (I) wherein R is (C1-C5) alkyl or CH3(CH2)nCO and n is 1, 2, 3 or 4 are useful in treating gastroduodenal diseases such as gastric ulcers, duodenal ulcers and gastric cancer caused by Helicobacter pylori. Spirolaxine and spirolaxine methyl ether are isolated from the fermentation of Sporotrichum pruinosum ATCC 74278. Spirolaxine and the compounds of formula (I) are also useful in combination with H2 antagonist, colloidal bismuth subcitrate and other antibiotics.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: April 16, 2002
    Assignee: Pfizer Inc.
    Inventors: Mark A. Guadliana, Liang H. Huang, Takushi Kaneko, Paul C. Watts
  • Publication number: 20020040007
    Abstract: This invention relates to compounds of the formula 1
    Type: Application
    Filed: October 1, 2001
    Publication date: April 4, 2002
    Inventor: Takushi Kaneko
  • Publication number: 20020016297
    Abstract: The present invention relates to compounds of the formula 1 1
    Type: Application
    Filed: December 20, 2000
    Publication date: February 7, 2002
    Inventors: Robert G. Linde, Matthew Merrill Hayward, Takushi Kaneko
  • Patent number: 6300316
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: October 9, 2001
    Assignee: Pfizer Inc
    Inventors: Katherine E. Brighty, Takushi Kaneko, Robert G. Linde, II, Hiroko Masamune, Paul R. McGuirk, Wei-Guo Su, Yong-Jin Wu, Bingwei V. Yang
  • Patent number: 6258785
    Abstract: The invention relates to crystalline 9-E-(O-methyl)oxime of 11,12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-&agr;-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl)hydrazono))-3-oxoerythromycin wherein said crystalline compound is as the free base of said compound, the hemihydrate of said compound or the mesylate (methanesufonic acid) salt of said compound. The invention also relates to pharmaceutical compositions containing the foregoing crystalline compound and to methods of treating bacterial and protozoa infections by administering said crystalline compound.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: July 10, 2001
    Assignee: Pfizer Inc.
    Inventors: Wei-Guo Su, Takushi Kaneko, Yong-Jin Wu, Daniel J. Durkin, Kathleen T. Smyth
  • Patent number: 6174710
    Abstract: Spirolaxine, the compound of formula (I) wherein R is H, and the novel compounds of formula (I) wherein R is (C1-C6)alkyl or CH3(CH2)nCO and n is 1, 2, 3 or 4 are useful in treating gastroduodenal diseases such as gastric ulcers, duodenal ulcers and gastric cancer caused by Helicobacter pylori. Spirolaxine and spirolaxine methyl ether are isolated from the fermentation of Sporotrichum pruinosum ATCC 74278. Spirolaxine and the compounds of formula (I) are also useful in combination with H2 antagonist colloidal bismuth subcitrate and other antibiotics.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: January 16, 2001
    Assignee: Pfizer Inc.
    Inventors: Mark A. Guadliana, Liang H. Huang, Takushi Kaneko, Paul C. Watts
  • Patent number: 6130217
    Abstract: This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: October 10, 2000
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Jotham Wadsworth Coe, Takushi Kaneko, Mikel Paul Moyer
  • Patent number: 6074855
    Abstract: Processes for preparing spirolaxine and spirolaxine methyl ether, the compounds of formulas (I) and (II) respectively, ##STR1## comprising fermenting fungi selected from the group consisting of Sporotrichum pruinosum FD 29585, ATCC 74327; Sporotrichum pruinosum FD 29454, ATCC 74329; Sporotrichun pruinosum FD 29586, ATCC 74328; and Phanerochaete chrysosporiun LN 3576, ATCC 74326. This invention also relates to a process for preparing spirolaxine comprising fermenting Sporotrichum pruinosum FD 29458, ATCC 74330.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: June 13, 2000
    Assignee: Pfizer Inc.
    Inventors: Mark A. Guadliana, Liang H. Huang, Takushi Kaneko
  • Patent number: 5773435
    Abstract: The instant invention relates to a novel method for the delivery of antitumor drugs to tumor cells by the administration of a tumor-selective antibody-.beta.-lactamase conjugate that binds to tumor cells, and the additional administration of a cephalosporin prodrug that is converted at the tumor site, in the presence of the antibody-.beta.-lactamase, to an active cytotoxic drug. According to the preferred embodiment of this invention, a cephalosporin mustard has been constructed which when cleaved by .beta.-lactamase yields a cytotoxic nitrogen mustard. The methods, antibody-enzyme conjugate, prodrugs, pharmaceutical compositions, and combinations of this invention provide for enhanced selective killing of tumor cells and are thus useful in the treatment of cancers and other tumors.
    Type: Grant
    Filed: February 9, 1993
    Date of Patent: June 30, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: John Kadow, Takushi Kaneko, Peter D. Senter, Vivekanada M. Vrudhula